This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robertson, M. J. Articles by Ritz, J. Search for Related Content PubMed PubMed Citation Articles by Robertson, M. J. Articles by Ritz, J.

Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Michael J. Robertson, M.D., Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. Telephone: 617-632-3768; Fax: 617-632-5167; e-mail: michael_robertson{at}dfci.harvard.edu

Interleukin 12 is a heterodimeric cytokine that has potent effects on innate and adaptive immunity. Interleukin 12 induces interferon secretion by T cells and natural killer cells, enhances the proliferation of activated T cells and natural killer cells, augments the cytolytic activity of cytotoxic T lymphocytes and natural killer cells, and supports the differentiation of Th1 helper effector cells. Interleukin 12 stimulates in vitro antitumor activity of lymphocytes from patients with cancer and in vivo antitumor activity in many murine tumor models. Current data indicate that CD4 T cells, CD8 T cells, natural killer cells and interferon may contribute to the antitumor effects of interleukin 12 therapy. However, further investigation is required to elucidate the precise mechanisms involved in the antitumor activity of interleukin 12.

Key Words. Interleukin 12 (IL-12) • Immunotherapy • Biologic therapy • Cytokine therapy • Tumor immunology • Antitumor immunity

This article has been cited by other articles:

				S. D. Sharma, S. M. Meeran, N. Katiyar, G. B. Tisdale, N. Yusuf, H. Xu, C. A. Elmets, and S. K. Katiyar IL-12 deficiency suppresses 12-O-tetradecanoylphorbol-13-acetate-induced skin tumor development in 7,12-dimethylbenz(a)anthracene-initiated mouse skin through inhibition of inflammation Carcinogenesis, November 1, 2009; 30(11): 1970 - 1977. [Abstract] [Full Text] [PDF]

				Z. Chen, J. Lu, N. Srinivasan, B. K. H. Tan, and S. H. Chan Polysaccharide-Protein Complex from Lycium barbarum L. Is a Novel Stimulus of Dendritic Cell Immunogenicity J. Immunol., March 15, 2009; 182(6): 3503 - 3509. [Abstract] [Full Text] [PDF]

				S. M. Meeran, S. Katiyar, C. A. Elmets, and S. K. Katiyar Interleukin-12 Deficiency Is Permissive for Angiogenesis in UV Radiation-Induced Skin Tumors Cancer Res., April 15, 2007; 67(8): 3785 - 3793. [Abstract] [Full Text] [PDF]

				W. R. Coward, A. Marei, A. Yang, M. M. Vasa-Nicotera, and S. C. Chow Statin-Induced Proinflammatory Response in Mitogen-Activated Peripheral Blood Mononuclear Cells through the Activation of Caspase-1 and IL-18 Secretion in Monocytes J. Immunol., May 1, 2006; 176(9): 5284 - 5292. [Abstract] [Full Text] [PDF]

				S. M. Meeran, S. K. Mantena, S. Meleth, C. A. Elmets, and S. K. Katiyar Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol. Cancer Ther., April 1, 2006; 5(4): 825 - 832. [Abstract] [Full Text] [PDF]

				S. M. Meeran, S. K. Mantena, and S. K. Katiyar Prevention of Ultraviolet Radiation-Induced Immunosuppression by (-)-Epigallocatechin-3-Gallate in Mice Is Mediated through Interleukin 12-Dependent DNA Repair. Clin. Cancer Res., April 1, 2006; 12(7): 2272 - 2280. [Abstract] [Full Text] [PDF]

				H. Kasai, L. M. He, M. Kawamura, P. T. Yang, X. W. Deng, M. Munkanta, A. Yamashita, H. Terunuma, M. Hirama, I. Horiuchi, et al. IL-12 Production Induced by Agaricus blazei Fraction H (ABH) Involves Toll-like Receptor (TLR) Evid. Based Complement. Altern. Med., December 1, 2004; 1(3): 259 - 267. [Abstract] [Full Text] [PDF]

				C. N. Baxevanis, A. D. Gritzapis, and M. Papamichail In Vivo Antitumor Activity of NKT Cells Activated by the Combination of IL-12 and IL-18 J. Immunol., September 15, 2003; 171(6): 2953 - 2959. [Abstract] [Full Text] [PDF]

				M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma Clin. Cancer Res., August 1, 2001; 7(8): 2195 - 2204. [Abstract] [Full Text] [PDF]

				M. J. Smyth, M. Taniguchi, and S. E. A. Street The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent J. Immunol., September 1, 2000; 165(5): 2665 - 2670. [Abstract] [Full Text] [PDF]

				W. M. Siders, P. W. Wright, J. A. Hixon, W. G. Alvord, T. C. Back, R. H. Wiltrout, and R. G. Fenton T Cell- and NK Cell-Independent Inhibition of Hepatic Metastases by Systemic Administration of an IL-12-Expressing Recombinant Adenovirus J. Immunol., June 1, 1998; 160(11): 5465 - 5474. [Abstract] [Full Text] [PDF]